Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome-Reference-Cited by-同舟云学术

Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome

Published:2021-01-20 Issue:3 Volume:41 Page:279-283
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Ju Wu‐tong¹²,Liu Ying¹²,Wang Li‐zhen³,Li Jiang³,Ren Guo‐xing¹²,Sun Jian¹²,Tu Wen‐yong¹²,Hu Yong‐jie¹²,Ji Tong¹²,Yang Wen‐jun¹²,Li Jun¹²,He Yue¹²,Wang Yan‐an¹²,Zhang Chen‐ping¹²,Zhong Lai‐ping¹²^ORCID,Zhang Zhi‐yuan¹²

Affiliation:

1. Department of Oral and Maxillofacial‐Head and Neck Oncology Ninth People's Hospital College of Stomatology Shanghai Jiao Tong University School of Medicine Shanghai 200011 P. R. China

2. National Clinical Research Center for Oral Diseases Shanghai Key Laboratory of Stomatology Shanghai 200011 P. R. China

3. Department of Oral Pathology Ninth People's Hospital College of Stomatology Shanghai Jiao Tong University School of Medicine Shanghai 200011 P. R. China

Funder

National Natural Science Foundation of China

Shanghai Municipal Education Commission

Program of Shanghai Academic Research Leader

School of Medicine, Shanghai Jiao Tong University

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12136

Reference10 articles.